The article discusses a research study which examined the cost-effectiveness of pneumococcal conjugate vaccines of 7, 10 and 13 valences in Colombian children, published in the January 19, 2012 issue of the journal "Vaccine."EBSCO_AspPharmacoeconomics & Outcomes News...
Benefits of pneumococcal conjugate vaccine programs have been linked to the vaccine’s ability to disrupt nasopharyngeal carriage and transmission. The 10-valent pneumococcal vaccine (PCV10) was included in the Expanded Program on Immunization (EPI) in S
Therefore, vaccine uptake must be high enough to be able to affect serotype distribution/IPD incidence rates at the population level [18,19] and to represent the experience of countries with high coverage. It also serves to help eliminate heterogeneous results due to coverage to enable focus on...
Our overall objective was therefore to evaluate safety and immunogenicity of a combination PCV schedule of PHiD-CV10 (S) given at 1–2–4 months plus PCV13 (P) given at 6 months (SSSP) compared to either vaccine alone when given at 2–4-6 months (_SSS or _PPP). The aim being to...
Nhantumbo AA, Weldegebriel G, Katsande R, et al. Surveillance of impact of PCV-10 vaccine on pneumococcal meningitis in Mozambique, 2013-2015. PLoS One. 2017;12:e0177746.Nhantumbo AA, Weldegebriel G, Katsande R, de Gouveia L, Come CE, Cuco AZ, et al. Surveillance of impact of PCV...
(2) significant increase of serotype 19A (from 1.6% to 14.8%) and less important increase of serotype 3 (from 10.5% to 14.5%) and non-vaccine serotypes (NVT) (from 21.4% to 38.4%) non-significant; and (3) meningitis and non-meningitis multidrug resistant isolates associated with serotype...
The 10-valent pneumococcal vaccine (PCV10) has been introduced in the national immunization program (2+1 schedule: 6 and 10 weeks, and 9 months) in Nepal since 2015. The impact of PCV10 on hospital admission due to pneumonia is not well known in Nepal. METHODS. A cross-sectional study ...
The meningococcal C conjugate vaccine (MCC) was introduced in November 2010, scheduled at 3 and 5 months, with a booster dose at 12-15 months of age and no catch-up for older age groups. In this interrupted time-series analysis study, we used Brazilian mortality data from 2005 to 2015 ...
While the PCV10 vaccine was introduced in Pakistan in October 2012, data regarding the impact of the vaccine on the population dynamics of Streptococcus pneumoniae in Pakistan remain obscure. Using whole genome sequencing of 190 isolates (nasopharyngeal carriage=75, disease=113,unknown sites=2) ...
VACCINERESISTANCEPurpose: The non-invasive pneumococcal disease (NIPD) is a common infection during childhood. We aimed to define the clonal spread of pediatric non-invasive isolates recovered during the PCV10-period in Bulgaria concerning the serotype and antimicrobial susceptibility. Materials and ...